In February 2013 we learned of two mesothelioma drugs under development for possible future use as treatment alternatives.
First, from a February 12, 2013 report published online by FierceDrugDelivery, “Genelux, Sloan-Kettering test delivery of mesothelioma drug”, we were introduced to GL-ONC1, which might also eventully be used at the diagnosis stage.
From that article about GL-ONC1 for mesothelioma:
California-based Genelux is helming a first-in-man trial of its new mesothelioma treatment at Memorial Sloan-Kettering Cancer Center in New York.
The center has begun injecting the drug, GL-ONC1, into the cavity surrounding the lungs to treat the rare and aggressive form of cancer called mesothelioma, which can occur as a result of exposure to asbestos. Patients suffering from mesothelioma may experience a buildup of fluid around the lungs, and the dose of GL-ONC1 is designed to temper those symptoms. It marks the first time the drug will be delivered in such a way.
GL-ONC1, according to the company, is both a treatment and a diagnostic–a genetically modified vaccinia virus, it produces a green fluorescent protein that can be tracked within the patient to determine the expression of the disease.
Next, we refer you to a drug company press release issued in February 2013, “Verastem Files for Orphan Disease Status for VS-6063 in Mesothelioma”:
Verastem is seeking orphan drug designation in the US and the EU for the use of VS-6063 in mesothelioma. VS-6063 is anticipated to enter a potentially pivotal study in mesothelioma midyear 2013….
VS-6063 is an oral small molecule inhibitor of focal adhesion kinase (FAK), which is a critical pathway for cancer stem cells. VS-6063 was well-tolerated and demonstrated signs of clinical activity in a Phase 1 study in advanced solid tumors. VS-6063 is currently in a Phase 1/2 study in patients with advanced ovarian cancer, where VS-6063 is being tested in combination with paclitaxel.
We will continue to watch for new possible mesothelioma treatments as the year goes on and let you know about those here on Asbestos HUB.
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.